Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Sachin Narain

Interventional Pain Medicine Gilbert, AZ Medical Doctor

NPI 1790009231 CMS profile 1379056

3645 S Rome St Ste 216, Ste 104, Gilbert, AZ 85297

Open in the dashboard

General payments

$31,294

618 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sachin Narain of Gilbert, AZ is reported in the CMS Open Payments database as having received $31,294 across 618 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $6,536 45
2024 General $11,150 66
2023 General $4,582 132
2022 General $2,858 138
2021 General $2,045 106
2020 General $3,120 60
2019 General $1,003 71

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sachin Narain
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Sachin Narain were reported at $6,536. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Sachin Narain Interventional Pain Medicine median Middle half National median
2019 $1,003 $684 $216–$2,079 $163
2020 $3,120 $382 $122–$1,109 $114
2021 $2,045 $552 $167–$1,554 $132
2022 $2,858 $605 $187–$1,924 $149
2023 $4,582 $671 $195–$1,915 $160
2024 $11,150 $684 $206–$1,837 $164
2025 $6,536 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $20,960 358 payments
  2. Spinefrontier, Inc. $2,463 9 payments
  3. ImpactOrtho, Inc. $2,193 3 payments
  4. Painteq LLC $1,253 29 payments
  5. Boston Scientific Corporation $1,167 57 payments
  6. Nevro Corp. $584 41 payments
  7. Vertos Medical, Inc. $400 3 payments
  8. Salix Pharmaceuticals, a division of Bausch Health US, LLC $296 19 payments
  9. BIOTRONIK NRO, Inc. $226 8 payments
  10. Nalu Medical, Inc. $202 6 payments
  11. Other $1,550 85 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $14,297 6 payments
  2. Food and Beverage $12,565 604 payments
  3. Education $2,599 6 payments
  4. Travel and Lodging $1,834 2 payments
Products named General payments · program years 2019–2025
  1. PROCLAIM Neuromodulation $12,633 184 payments
  2. PROCLAIM Structural Heart $2,847 12 payments
  3. PRODIGY $2,500 1 payment
  4. Sacrix $1,878 3 payments
  5. PAINTEQ $1,253 29 payments
  6. Proclaim IPG $987 58 payments
  7. Proclaim Family of SCS IPGs $926 60 payments
  8. SIJFuse $585 6 payments
  9. NanoFUSE $585 6 payments
  10. Inspan $585 6 payments
  11. Other $6,040 265 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 23 drugs

Part D claims

2,135

Median for Pain Management: 951

Drug cost

$44,902

Median for Pain Management: $26,034

Branded share of claims

31.7%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 381 $9,189
Xtampza Er Oxycodone Myristate Brand 18 $7,278
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 206 $5,389
Gabapentin Generic 282 $4,165
Pregabalin Generic 111 $3,163
Diclofenac Sodium Generic 137 $2,496
Oxycodone Hcl Generic 153 $2,267
Tizanidine Hcl Generic 178 $2,226
Morphine Sulfate Er Morphine Sulfate Brand 59 $1,398
Mupirocin Generic 126 $964

The 10 drugs with the highest cost, of 23 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 63 billing codes

Paid by Medicare

$188,051

Of which drugs: $157

Medicare patients

369

Average age 71

Services billed

2,755

230 women, 139 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 34%
Depression 31%
Ischemic heart disease 29%
Chronic kidney disease 27%
Osteoporosis 20%
COPD 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 57 595 $53

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ROXYBOND
  • PROTEGA PHARMACEUTIALS LLC $70
$70 — —
RELISTOR
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $48
$48 — —
ZTLido
  • Scilex Pharmaceuticals Inc. $17
$17 — —
Tirosint
  • IBSA Pharma Inc. $7
$7 — —
Licart
  • IBSA Pharma Inc. $7
$7 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

618 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record